<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38671455</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development.</ArticleTitle><Pagination><StartPage>98</StartPage><MedlinePgn>98</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">98</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-024-02370-6</ELocationID><Abstract><AbstractText>About four years have passed since the detection of the first cases of COVID-19 in China. During this lethal pandemic, millions of people have lost their lives around the world. Since the first waves of COVID-19 infection, various pharmacotherapeutic agents have been examined in the management of COVID-19. Despite all these efforts in pharmacotherapy, drug repurposing, and design and development of new drugs, multiple organ involvement and various complications occurred during COVID-19. Some of these complications became chronic and long-lasting which led to the "long COVID" syndrome appearance. Therefore, the best way to eradicate this pandemic is prophylaxis through mass vaccination. In this regard, various vaccine platforms including inactivated vaccines, nucleic acid-based vaccines (mRNA and DNA vaccines), adenovirus-vectored vaccines, and protein-based subunit vaccines have been designed and developed to prevent or reduce COVID-19 infection, hospitalization, and mortality rates. In this focused review, at first, the most commonly reported clinical presentations of COVID-19 during these four years have been summarized. In addition, different therapeutic regimens and their latest status in COVID-19 management have been listed. Furthermore, the "long COVID" and related signs, symptoms, and complications have been mentioned. At the end, the effectiveness of available COVID-19 vaccines with different platforms against early SARS-CoV-2 variants and currently circulating variants of interest (VOI) and the necessity of booster vaccine shots have been summarized and discussed in more detail.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghasemiyeh</LastName><ForeName>Parisa</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8640-5724</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi-Samani</LastName><ForeName>Soliman</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1007-1422</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. smsamani@sums.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. smsamani@sums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087506" MajorTopicYN="Y">Vaccine Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">COVID-19 variants</Keyword><Keyword MajorTopicYN="N">Clinical presentation</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Pharmacotherapy</Keyword><Keyword MajorTopicYN="N">Vaccine effectiveness (VE)</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>26</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38671455</ArticleId><ArticleId IdType="pmc">PMC11055380</ArticleId><ArticleId IdType="doi">10.1186/s12985-024-02370-6</ArticleId><ArticleId IdType="pii">10.1186/s12985-024-02370-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020&#x2013;21. Lancet. 2022;399(10334):1513&#x2013;36. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa-Hedeab G. ACE2 as drug target of COVID-19 virus treatment, simplified updated review. Rep Biochem Mol Biology. 2020;9(1):97. doi: 10.29252/rbmb.9.1.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.29252/rbmb.9.1.97</ArticleId><ArticleId IdType="pmc">PMC7424417</ArticleId><ArticleId IdType="pubmed">32821757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W-L, Toh HS, Liao C-T, Chang W-T. Cardiovascular complications of COVID-19 and associated concerns: a review. Acta Cardiol Sinica. 2021;37(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814323</ArticleId><ArticleId IdType="pubmed">33488023</ArticleId></ArticleIdList></Reference><Reference><Citation>Page EM, Ari&#xeb;ns RA. Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thromb Res. 2021;200:1&#x2013;8. doi: 10.1016/j.thromres.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7813504</ArticleId><ArticleId IdType="pubmed">33493983</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Jing H, Wu X, Xiang M, Novakovic VA, Wang S et al. The cross-talk of lung and heart complications in COVID-19: endothelial cells dysfunction, thrombosis, and treatment. Front Cardiovasc Med. 2022;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9390946</ArticleId><ArticleId IdType="pubmed">35990983</ArticleId></ArticleIdList></Reference><Reference><Citation>Shehata GA, Lord KC, Grudzinski MC, Elsayed M, Abdelnaby R, Elshabrawy HA. Neurological complications of COVID-19: underlying mechanisms and management. Int J Mol Sci. 2021;22(8):4081. doi: 10.3390/ijms22084081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22084081</ArticleId><ArticleId IdType="pmc">PMC8071289</ArticleId><ArticleId IdType="pubmed">33920904</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Karmalawy AA, Soltane R, Abo Elmaaty A, Tantawy MA, Antar SA, Yahya G, et al. Coronavirus disease (COVID-19) control between drug repurposing and vaccination: a comprehensive overview. Vaccines. 2021;9(11):1317. doi: 10.3390/vaccines9111317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9111317</ArticleId><ArticleId IdType="pmc">PMC8622998</ArticleId><ArticleId IdType="pubmed">34835248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashour NA, Abo Elmaaty A, Sarhan AA, Elkaeed EB, Moussa AM, Erfan IA et al. A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval. Drug design, development and therapy. 2022:685&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935998</ArticleId><ArticleId IdType="pubmed">35321497</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritonavir-Boosted Nirmatrelvir. (Paxlovid) [ https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/.</Citation></Reference><Reference><Citation>Ghasemiyeh P, Mohammadi-Samani S. COVID-19 outbreak: challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. Heart Lung. 2020;49(6):763&#x2013;73. doi: 10.1016/j.hrtlng.2020.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrtlng.2020.08.025</ArticleId><ArticleId IdType="pmc">PMC7500907</ArticleId><ArticleId IdType="pubmed">32980626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I, Mohammadi-Samani S, Vazin A, Safari A, et al. Major neurologic adverse drug reactions, potential drug&#x2013;drug interactions and pharmacokinetic aspects of drugs used in covid-19 patients with stroke: a narrative review. Ther Clin Risk Manag. 2020;16:595. doi: 10.2147/TCRM.S259152.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S259152</ArticleId><ArticleId IdType="pmc">PMC7335700</ArticleId><ArticleId IdType="pubmed">32669846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemiyeh P, Mortazavi N, Karimzadeh I, Vazin A, Mahmoudi L, Moghimi-Sarani E, et al. Psychiatric adverse drug reactions and potential Anti-COVID-19 drug interactions with psychotropic medications. Iran J Pharm Research: IJPR. 2021;20(3):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653652</ArticleId><ArticleId IdType="pubmed">34903970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemiyeh P, Mohammadi-Samani S. Iron chelating agents: promising supportive therapies in severe cases of COVID-19? Trends Pharm Sci. 2020;6(2):65&#x2013;6.</Citation></Reference><Reference><Citation>Ghasemiyeh P, Mohammadi-Samani S, Vazin A. Micronutrients supplementation in pregnant women during COVID-19 pandemy: pros and cons. Trends Pharm Sci. 2021;7(3):153&#x2013;60.</Citation></Reference><Reference><Citation>Zarkesh K, Entezar-Almahdi E, Ghasemiyeh P, Akbarian M, Bahmani M, Roudaki S, et al. Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiol. 2021;16(18):1415&#x2013;51. doi: 10.2217/fmb-2021-0116.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2021-0116</ArticleId><ArticleId IdType="pmc">PMC8610072</ArticleId><ArticleId IdType="pubmed">34812049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemiyeh P, Mohammadi-Samani S. The necessity of early anti-inflammatory therapy initiation in cases with mild-to-moderate COVID-19: a personal experience from an attending pharmacist and his resident. Acta Bio-medica: Atenei Parmensis. 2021;92(3):e2021250&#x2013;e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343756</ArticleId><ArticleId IdType="pubmed">34212899</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetter P, Vu DL, L&#x2019;Huillier AG, Schibler M, Kaiser L, Jacquerioz F. Clinical features of covid-19. British Medical Journal Publishing Group; 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32303495</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelaia C, Tinello C, Vatrella A, De Sarro G, Pelaia G. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. Ther Adv Respir Dis. 2020;14:1753466620933508. doi: 10.1177/1753466620933508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753466620933508</ArticleId><ArticleId IdType="pmc">PMC7298425</ArticleId><ArticleId IdType="pubmed">32539627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals. 2021;14(8):807. doi: 10.3390/ph14080807.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14080807</ArticleId><ArticleId IdType="pmc">PMC8398080</ArticleId><ArticleId IdType="pubmed">34451904</ArticleId></ArticleIdList></Reference><Reference><Citation>Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Translational Res. 2020;226:57&#x2013;69. doi: 10.1016/j.trsl.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7438210</ArticleId><ArticleId IdType="pubmed">32827705</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih AR, Misdraji J. COVID-19: gastrointestinal and hepatobiliary manifestations. Hum Pathol. 2023;132:39&#x2013;55. doi: 10.1016/j.humpath.2022.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humpath.2022.07.006</ArticleId><ArticleId IdType="pmc">PMC9288242</ArticleId><ArticleId IdType="pubmed">35843340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020;52(7):345&#x2013;53. doi: 10.1080/07853890.2020.1790643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2020.1790643</ArticleId><ArticleId IdType="pmc">PMC7877945</ArticleId><ArticleId IdType="pubmed">32643418</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjonbalaj N, Uka S, Olluri E, Sulovari A, Vishaj M, Kamberi L, et al. Renal artery thrombosis as a long-term complication of COVID-19. Radiol Case Rep. 2023;18(1):260&#x2013;5. doi: 10.1016/j.radcr.2022.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radcr.2022.10.028</ArticleId><ArticleId IdType="pmc">PMC9631237</ArticleId><ArticleId IdType="pubmed">36345461</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020;141(23):1930&#x2013;6. doi: 10.1161/CIRCULATIONAHA.120.047164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047164</ArticleId><ArticleId IdType="pmc">PMC7314498</ArticleId><ArticleId IdType="pubmed">32243205</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504&#x2013;7. doi: 10.1016/j.ajem.2020.04.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.04.048</ArticleId><ArticleId IdType="pmc">PMC7165109</ArticleId><ArticleId IdType="pubmed">32317203</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheraton M, Deo N, Kashyap R, Surani S. A review of neurological complications of COVID-19. Cureus. 2020;12(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243063</ArticleId><ArticleId IdType="pubmed">32455089</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagu P, Parashar A, Behl T, Mehta V. CNS implications of COVID-19: a comprehensive review. Rev Neurosci. 2021;32(2):219&#x2013;34. doi: 10.1515/revneuro-2020-0070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2020-0070</ArticleId><ArticleId IdType="pubmed">33550782</ArticleId></ArticleIdList></Reference><Reference><Citation>Guck AJ, Buck K, Lehockey K. Psychological complications of COVID-19 following hospitalization and ICU discharge: recommendations for treatment. Professional Psychology: Research and Practice; 2021.</Citation></Reference><Reference><Citation>Alahyari S, Moradi M, Rajaeinejad M, Jalaeikhoo H. Post-COVID-19 hematologic complications: a systematic review. Expert Rev Hematol. 2022(just-accepted).</Citation><ArticleIdList><ArticleId IdType="pubmed">35584541</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanaroff AC, Lopes RD. COVID-19 thrombotic complications and therapeutic strategies. Annu Rev Med. 2023;74:15&#x2013;30. doi: 10.1146/annurev-med-042921-110257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042921-110257</ArticleId><ArticleId IdType="pubmed">36130046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouzid D, Visseaux B, Kassasseya C, Daoud A, F&#xe9;my F, Hermand C, et al. Comparison of patients infected with Delta versus Omicron COVID-19 variants presenting to Paris emergency departments: a retrospective cohort study. Ann Intern Med. 2022;175(6):831&#x2013;7. doi: 10.7326/M22-0308.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-0308</ArticleId><ArticleId IdType="pmc">PMC8941485</ArticleId><ArticleId IdType="pubmed">35286147</ArticleId></ArticleIdList></Reference><Reference><Citation>Therapeutic Management of Nonhospitalized Adults With COVID. -19 [ https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/#:~:text=The%20Panel%20recommends%20using%20nirmatrelvir,of%20symptom%20onset%20(%20AIIa%20).</Citation></Reference><Reference><Citation>Therapeutic Management of Hospitalized Adults With COVID. -19 [ https://www.covid19treatmentguidelines.nih.gov/tables/therapeutic-management-of-hospitalized-adults/.</Citation></Reference><Reference><Citation>Coronavirus Disease. 2019 (COVID-19) Treatment Guidelines [ https://www.covid19treatmentguidelines.nih.gov/.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612&#x2013;20. doi: 10.1001/jamainternmed.2021.6203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6203</ArticleId><ArticleId IdType="pmc">PMC8498934</ArticleId><ArticleId IdType="pubmed">34617959</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiruchelvam K, Kow CS, Hadi MA, Hasan SS. The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. Expert Rev anti-infective Therapy. 2022;20(2):211&#x2013;29. doi: 10.1080/14787210.2021.1949984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2021.1949984</ArticleId><ArticleId IdType="pmc">PMC8477583</ArticleId><ArticleId IdType="pubmed">34192469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupte V, Hegde R, Sawant S, Kalathingal K, Jadhav S, Malabade R, et al. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infect Dis. 2022;22(1):1&#x2013;8. doi: 10.1186/s12879-021-07004-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-07004-8</ArticleId><ArticleId IdType="pmc">PMC8724590</ArticleId><ArticleId IdType="pubmed">34983406</ArticleId></ArticleIdList></Reference><Reference><Citation>Remdesivir [Available from. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/remdesivir/.</Citation></Reference><Reference><Citation>Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54(1):516&#x2013;23. doi: 10.1080/07853890.2022.2034936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2034936</ArticleId><ArticleId IdType="pmc">PMC8820829</ArticleId><ArticleId IdType="pubmed">35118917</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanne JH. Covid-19: FDA authorises pharmacists to prescribe Paxlovid. British Medical Journal Publishing Group; 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35803606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509&#x2013;20. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>McCreary EK, Kip KE, Collins K, Minnier TE, Snyder GM, Steiner A, et al. editors. Evaluation of Bebtelovimab for treatment of COVID-19 during the SARS-CoV-2 Omicron variant era. Open Forum Infectious Diseases; 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9619560</ArticleId><ArticleId IdType="pubmed">36324319</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozani PS, Sheikhi M, Baharifar N, Shokoohi SD, Sheikhi S, Mirarefin SMJ et al. Bebtelovimab: the FDA-approved monoclonal antibody for treating patients with mild-to-moderate COVID-19. Trends Med Sci. 2022;2(3).</Citation></Reference><Reference><Citation>Vilobelimab [Available from. https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/.</Citation></Reference><Reference><Citation>Kuritzkes DR. Bamlanivimab for Prevention of COVID-19. JAMA. 2021;326(1):31&#x2013;2. doi: 10.1001/jama.2021.7515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7515</ArticleId><ArticleId IdType="pubmed">34081075</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman GA, O&#x2019;Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, et al. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2022;22(10):1444&#x2013;54. doi: 10.1016/S1473-3099(22)00416-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00416-9</ArticleId><ArticleId IdType="pmc">PMC9255947</ArticleId><ArticleId IdType="pubmed">35803290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao G, Li A, Wang Y, Tran C, Qi X. Lack of efficacy for sotrovimab use in patients with COVID-19: a meta-analysis. J Infect. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021041</ArticleId><ArticleId IdType="pubmed">35461909</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorda A, Kussmann M, Kolenchery N, Siller-Matula JM, Zeitlinger M, Jilma B, et al. Convalescent plasma treatment in patients with Covid-19: a systematic review and Meta-analysis. Front Immunol. 2022;13:817829. doi: 10.3389/fimmu.2022.817829.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.817829</ArticleId><ArticleId IdType="pmc">PMC8859444</ArticleId><ArticleId IdType="pubmed">35197981</ArticleId></ArticleIdList></Reference><Reference><Citation>Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis. JAMA Netw open. 2022;5(1):e2147331&#x2013;e. doi: 10.1001/jamanetworkopen.2021.47331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.47331</ArticleId><ArticleId IdType="pmc">PMC8790669</ArticleId><ArticleId IdType="pubmed">35076699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkham AM, Bailey AJ, Monaghan M, Shorr R, Lalu MM, Fergusson DA, et al. Updated Living Systematic Review and Meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a Framework for Accelerated Synthesis of Trial evidence for Rapid Approval&#x2014;FASTER approval. Stem Cells Translational Med. 2022;11(7):675&#x2013;87. doi: 10.1093/stcltm/szac038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/stcltm/szac038</ArticleId><ArticleId IdType="pmc">PMC9299509</ArticleId><ArticleId IdType="pubmed">35758400</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorward J, Yu L-M, Hayward G, Saville BR, Gbinigie O, Van Hecke O, et al. Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. Br J Gen Pract. 2022;72(720):e446&#x2013;55. doi: 10.3399/BJGP.2022.0083.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/BJGP.2022.0083</ArticleId><ArticleId IdType="pmc">PMC9037186</ArticleId><ArticleId IdType="pubmed">35440469</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaith HS, Gabra MD, Nafady MH, Elshawah HE, Negida A, Mushtaq G et al. A review of the rational and current evidence on colchicine for COVID-19. Curr Pharm Design. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">34895117</ArticleId></ArticleIdList></Reference><Reference><Citation>Griesel M, Wagner C, Mikolajewska A, Stegemann M, Fichtner F, Metzendorf M-I et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst Reviews. 2022(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905579</ArticleId><ArticleId IdType="pubmed">35262185</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemency BM, Varughese R, Gonzalez-Rojas Y, Morse CG, Phipatanakul W, Koster DJ, et al. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA Intern Med. 2022;182(1):42&#x2013;9. doi: 10.1001/jamainternmed.2021.6759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6759</ArticleId><ArticleId IdType="pmc">PMC8609464</ArticleId><ArticleId IdType="pubmed">34807241</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyirenda JL, Sofroniou M, Toews I, Mikolajewska A, Lehane C, Monsef I et al. Fluvoxamine for the treatment of COVID-19. Cochrane Database Syst Reviews. 2022(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9473347</ArticleId><ArticleId IdType="pubmed">36103313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Chambers RC, Dagna L. Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe? Lancet Rheumatol. 2021;3(6):e394&#x2013;5. doi: 10.1016/S2665-9913(21)00078-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00078-3</ArticleId><ArticleId IdType="pmc">PMC7969129</ArticleId><ArticleId IdType="pubmed">33754142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TC, McDonald EG, Butler-Laporte G, Harrison LB, Cheng MP, Brophy JM. Remdesivir and systemic corticosteroids for the treatment of COVID-19: a bayesian re-analysis. Int J Infect Dis. 2021;104:671&#x2013;6. doi: 10.1016/j.ijid.2021.01.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.01.065</ArticleId><ArticleId IdType="pmc">PMC7849442</ArticleId><ArticleId IdType="pubmed">33540128</ArticleId></ArticleIdList></Reference><Reference><Citation>Noreen S, Maqbool I, Madni A, Dexamethasone Therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol. 2021;894:173854. doi: 10.1016/j.ejphar.2021.173854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.173854</ArticleId><ArticleId IdType="pmc">PMC7836247</ArticleId><ArticleId IdType="pubmed">33428898</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Guerra BA, Gonzalez-Lara MF, Roman-Montes CM, Tamez-Torres KM, Dard&#xf3;n-Fierro FE, Rajme-Lopez S, et al. Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. Emerg Microbes Infections. 2022;11(1):50&#x2013;9. doi: 10.1080/22221751.2021.2011619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2011619</ArticleId><ArticleId IdType="pmc">PMC8725849</ArticleId><ArticleId IdType="pubmed">34839785</ArticleId></ArticleIdList></Reference><Reference><Citation>Inhaled C. [ https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/inhaled-corticosteroids/.</Citation></Reference><Reference><Citation>Khani E, Shahrabi M, Rezaei H, Pourkarim F, Afsharirad H, Solduzian M. Current evidence on the use of anakinra in COVID-19. Int Immunopharmacol. 2022:109075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9296834</ArticleId><ArticleId IdType="pubmed">35905562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei Tolzali MM, Noori M, Shokri P, Rahmani S, Khanzadeh S, Nejadghaderi SA et al. Efficacy of tocilizumab in the treatment of COVID-19: an umbrella review. Rev Med Virol. 2022:e2388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539231</ArticleId><ArticleId IdType="pubmed">36029180</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41&#x2013;51. doi: 10.1001/jamainternmed.2020.6252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.6252</ArticleId><ArticleId IdType="pmc">PMC7577201</ArticleId><ArticleId IdType="pubmed">33080002</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406&#x2013;15. doi: 10.1056/NEJMoa2101643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101643</ArticleId><ArticleId IdType="pmc">PMC8220898</ArticleId><ArticleId IdType="pubmed">34133856</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Med. 2022;10(4):327&#x2013;36. doi: 10.1016/S2213-2600(22)00006-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00006-6</ArticleId><ArticleId IdType="pmc">PMC8813065</ArticleId><ArticleId IdType="pubmed">35123660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kifle ZD. Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: a review. Metabolism Open. 2021;11:100116. doi: 10.1016/j.metop.2021.100116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2021.100116</ArticleId><ArticleId IdType="pmc">PMC8318668</ArticleId><ArticleId IdType="pubmed">34345815</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021;76(9):907&#x2013;19. doi: 10.1136/thoraxjnl-2020-215266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215266</ArticleId><ArticleId IdType="pubmed">33579777</ArticleId></ArticleIdList></Reference><Reference><Citation>Caricchio R, Abbate A, Gordeev I, Meng J, Hsue PY, Neogi T, et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA. 2021;326(3):230&#x2013;9. doi: 10.1001/jama.2021.9508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.9508</ArticleId><ArticleId IdType="pmc">PMC8293025</ArticleId><ArticleId IdType="pubmed">34283183</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilia E, Belletti A, Fresilli S, Finco G, Landoni G. Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials. J Thromb Thrombolysis. 2022:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362611</ArticleId><ArticleId IdType="pubmed">35922578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogenboom WS, Lu JQ, Musheyev B, Borg L, Janowicz R, Pamlayne S, et al. Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19. PLoS ONE. 2022;17(1):e0262811. doi: 10.1371/journal.pone.0262811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262811</ArticleId><ArticleId IdType="pmc">PMC8769345</ArticleId><ArticleId IdType="pubmed">35045130</ArticleId></ArticleIdList></Reference><Reference><Citation>Antithrombotic Therapy in Patients With COVID. -19 [ https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/.</Citation></Reference><Reference><Citation>Spaetgens B, Nagy M, Ten Cate H. Antiplatelet therapy in patients with COVID-19&#x2014;more is less? JAMA. 2022;327(3):223&#x2013;4. doi: 10.1001/jama.2021.23866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.23866</ArticleId><ArticleId IdType="pubmed">35040901</ArticleId></ArticleIdList></Reference><Reference><Citation>Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Kidwai A, et al. Effect of antiplatelet therapy on survival and organ support&#x2013;free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1247&#x2013;59. doi: 10.1001/jama.2022.2910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.2910</ArticleId><ArticleId IdType="pmc">PMC8941448</ArticleId><ArticleId IdType="pubmed">35315874</ArticleId></ArticleIdList></Reference><Reference><Citation>Olczak-Pruc M, Swieczkowski D, Ladny JR, Pruc M, Juarez-Vela R, Rafique Z, et al. Vitamin C supplementation for the treatment of COVID-19: a systematic review and Meta-analysis. Nutrients. 2022;14(19):4217. doi: 10.3390/nu14194217.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14194217</ArticleId><ArticleId IdType="pmc">PMC9570769</ArticleId><ArticleId IdType="pubmed">36235869</ArticleId></ArticleIdList></Reference><Reference><Citation>Firouzi S, Pahlavani N, Navashenaq JG, Clayton ZS, Beigmohammadi MT, Malekahmadi M. The effect of vitamin C and zn supplementation on the immune system and clinical outcomes in COVID-19 patients. Clin Nutr Open Sci. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9233349</ArticleId><ArticleId IdType="pubmed">35783349</ArticleId></ArticleIdList></Reference><Reference><Citation>Balboni E, Zagnoli F, Filippini T, Fairweather-Tait SJ, Vinceti M. Zinc and selenium supplementation in COVID-19 prevention and treatment: a systematic review of the experimental studies. J Trace Elem Med Biol. 2022:126956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853960</ArticleId><ArticleId IdType="pubmed">35217499</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiner Sol&#xed;s &#xc1;, Avedillo Salas A, Luesma Bartolom&#xe9; MJ, Santander Ballest&#xed;n S. The effects of vitamin D supplementation in COVID-19 patients: a systematic review. Int J Mol Sci. 2022;23(20):12424. doi: 10.3390/ijms232012424.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232012424</ArticleId><ArticleId IdType="pmc">PMC9604062</ArticleId><ArticleId IdType="pubmed">36293279</ArticleId></ArticleIdList></Reference><Reference><Citation>Tentolouris N, Samakidou G, Eleftheriadou I, Tentolouris A, Jude EB. The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients. A systematic review, meta&#x2010;analysis and meta&#x2010;regression. Diab/Metab Res Rev. 2022;38(4):e3517. doi: 10.1002/dmrr.3517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3517</ArticleId><ArticleId IdType="pmc">PMC9015406</ArticleId><ArticleId IdType="pubmed">34965318</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Andrade B, Siqueira S, de Assis Soares WR, de Souza Rangel F, Santos NO, dos Santos Freitas A, et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13(4):700. doi: 10.3390/v13040700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040700</ArticleId><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Jahdhami I, Al-Naamani K, Al-Mawali A, Bennji SM. Respiratory complications after COVID-19. Oman Med J. 2022;37(1):e343. doi: 10.5001/omj.2022.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.5001/omj.2022.52</ArticleId><ArticleId IdType="pmc">PMC8907756</ArticleId><ArticleId IdType="pubmed">35282425</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z, Yang M, Lai C-L. Long COVID-19 syndrome: a comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans. Biomedicines. 2021;9(8):966. doi: 10.3390/biomedicines9080966.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080966</ArticleId><ArticleId IdType="pmc">PMC8394513</ArticleId><ArticleId IdType="pubmed">34440170</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper SL, Boyle E, Jefferson SR, Heslop CR, Mohan P, Mohanraj GG, et al. Role of the renin&#x2013;angiotensin&#x2013;aldosterone and kinin&#x2013;kallikrein systems in the cardiovascular complications of COVID-19 and long COVID. Int J Mol Sci. 2021;22(15):8255. doi: 10.3390/ijms22158255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158255</ArticleId><ArticleId IdType="pmc">PMC8347967</ArticleId><ArticleId IdType="pubmed">34361021</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan A, Wong F, Couch LS, Wang BX. Cardiac complications of COVID-19 in low-risk patients. Viruses. 2022;14(6):1322. doi: 10.3390/v14061322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061322</ArticleId><ArticleId IdType="pmc">PMC9228093</ArticleId><ArticleId IdType="pubmed">35746793</ArticleId></ArticleIdList></Reference><Reference><Citation>Elseidy SA, Awad AK, Vorla M, Fatima A, Elbadawy MA, Mandal D, et al. Cardiovascular complications in the Post-acute COVID-19 syndrome (PACS) IJC Heart Vasculature. 2022;40:101012. doi: 10.1016/j.ijcha.2022.101012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2022.101012</ArticleId><ArticleId IdType="pmc">PMC8958273</ArticleId><ArticleId IdType="pubmed">35355927</ArticleId></ArticleIdList></Reference><Reference><Citation>Korompoki E, Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Late&#x2010;onset hematological complications post COVID&#x2010;19: an emerging medical problem for the hematologist. Am J Hematol. 2022;97(1):119&#x2013;28. doi: 10.1002/ajh.26384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26384</ArticleId><ArticleId IdType="pmc">PMC8646944</ArticleId><ArticleId IdType="pubmed">34687462</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilis P, Vordoni A, Kalaitzidis RG. COVID-19 and kidney disease: a clinical perspective. Curr Vasc Pharmacol. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35570566</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19. Am J Physiology-Cell Physiol. 2022;322(1):C1&#x2013;11. doi: 10.1152/ajpcell.00375.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00375.2021</ArticleId><ArticleId IdType="pmc">PMC8721906</ArticleId><ArticleId IdType="pubmed">34817268</ArticleId></ArticleIdList></Reference><Reference><Citation>de Francisco &#xc1;M, Fresnedo GF. Long COVID-19 renal disease: A present medical need for nephrology. Nefrolog&#xed;a (English Edition). 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10060193</ArticleId><ArticleId IdType="pubmed">37031074</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A, Misra A. Post COVID-19 syndrome (long COVID) and diabetes: challenges in diagnosis and management. Diabetes Metabolic Syndrome: Clin Res Reviews. 2021;15(5):102235. doi: 10.1016/j.dsx.2021.102235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102235</ArticleId><ArticleId IdType="pmc">PMC8317446</ArticleId><ArticleId IdType="pubmed">34384972</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2. variants of concern as of 21 September 2023 [ https://www.ecdc.europa.eu/en/covid-19/variants-concern.</Citation></Reference><Reference><Citation>XBB.1.5. Updated Risk Assessment, 20 June 2023 [ https://www.who.int/docs/default-source/coronaviruse/20230620xbb.1.5.pdf?sfvrsn=fff6f686_3.</Citation></Reference><Reference><Citation>Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. Neutralization against BA. 2.75. 2, BQ. 1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2023;388(2):183&#x2013;5. doi: 10.1056/NEJMc2214293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214293</ArticleId><ArticleId IdType="pmc">PMC9812288</ArticleId><ArticleId IdType="pubmed">36546661</ArticleId></ArticleIdList></Reference><Reference><Citation>XBB.1.16. Updated Risk Assessment, 05 June 2023 [ https://www.who.int/docs/default-source/coronaviruse/05062023xbb.1.16.pdf?sfvrsn=f1845468_3.</Citation></Reference><Reference><Citation>EG.5 Updated Risk Evaluation, 21. September 2023 [ https://www.who.int/docs/default-source/coronaviruse/eg5-risk-evaluation.pdf?sfvrsn=6e9690e0_6.</Citation></Reference><Reference><Citation>Tracking SARS-. CoV-2 variants [ https://www.who.int/activities/tracking-SARS-CoV-2-variants.</Citation></Reference><Reference><Citation>Hoteit R, Yassine HM. Biological properties of SARS-CoV-2 variants: epidemiological impact and clinical consequences. Vaccines. 2022;10(6):919. doi: 10.3390/vaccines10060919.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060919</ArticleId><ArticleId IdType="pmc">PMC9230982</ArticleId><ArticleId IdType="pubmed">35746526</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre M, Lau L-S, Pokharel MD, Ramelow J, Owens F, Souchak J, et al. From alpha to omicron: how different variants of concern of the SARS-Coronavirus-2 impacted the world. Biology. 2023;12(9):1267. doi: 10.3390/biology12091267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology12091267</ArticleId><ArticleId IdType="pmc">PMC10525159</ArticleId><ArticleId IdType="pubmed">37759666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. Int Immunopharmacol. 2021;100:108162. doi: 10.1016/j.intimp.2021.108162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108162</ArticleId><ArticleId IdType="pmc">PMC8445802</ArticleId><ArticleId IdType="pubmed">34562844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsebom FC, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E, et al. COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England. The Lancet Infectious Diseases; 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129256</ArticleId><ArticleId IdType="pubmed">35623379</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L et al. BA. 2.12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection. Nature. 2022:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4, &amp; BA 5 Nat. 2022:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A, Huo J, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM et al. Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum. Cell. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) Update. FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose [ https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use.</Citation></Reference><Reference><Citation>Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81(4):495&#x2013;501. doi: 10.1007/s40265-021-01480-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01480-7</ArticleId><ArticleId IdType="pmc">PMC7938284</ArticleId><ArticleId IdType="pubmed">33683637</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiagarajan K. What do we know about India&#x2019;s Covaxin vaccine? BMJ. Br Med J (Online). 2021;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">33879478</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Sendra B, Albert E, Zulaica J, Torres I, Gim&#xe9;nez E, Botija P, et al. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. Sci Rep. 2022;12(1):1&#x2013;8. doi: 10.1038/s41598-022-07849-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-07849-2</ArticleId><ArticleId IdType="pmc">PMC8904770</ArticleId><ArticleId IdType="pubmed">35260713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm A, Toptan T, Pallas C, Wolf T, Goetsch U, Gottschalk R, et al. Antibody-mediated neutralization of authentic SARS-CoV-2 B. 1.617 variants harboring L452R and T478K/E484Q. Viruses. 2021;13(9):1693. doi: 10.3390/v13091693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13091693</ArticleId><ArticleId IdType="pmc">PMC8473269</ArticleId><ArticleId IdType="pubmed">34578275</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada T, Zhou H, Samanovic MI, Dcosta BM, Cornelius A, Mulligan MJ et al. Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants. BioRxiv. 2021.</Citation></Reference><Reference><Citation>Bassi J, Giannini O, Silacci-Fregni C, Pertusini L, Hitz P, Terrot T, et al. Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS ONE. 2022;17(2):e0263328. doi: 10.1371/journal.pone.0263328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263328</ArticleId><ArticleId IdType="pmc">PMC8830698</ArticleId><ArticleId IdType="pubmed">35143540</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio C, Malani PN, Omer SB. Confronting the delta variant of SARS-CoV-2, summer 2021. JAMA. 2021;326(11):1001&#x2013;2. doi: 10.1001/jama.2021.14811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.14811</ArticleId><ArticleId IdType="pubmed">34406361</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant. N Engl J Med. 2021;385(23):2195&#x2013;7. doi: 10.1056/NEJMc2113864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2113864</ArticleId><ArticleId IdType="pmc">PMC8552534</ArticleId><ArticleId IdType="pubmed">34670038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chagla Z. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19&#x2009;&#x2265;&#x2009;14 d after the 2nd dose. Ann Intern Med. 2021;174(3):JC28. doi: 10.7326/ACPJ202103160-028.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/ACPJ202103160-028</ArticleId><ArticleId IdType="pubmed">33646836</ArticleId></ArticleIdList></Reference><Reference><Citation>Grannis SJ, Rowley EA, Ong TC, Stenehjem E, Klein NP, DeSilva MB, et al. Interim estimates of COVID-19 vaccine effectiveness against COVID-19&#x2013;associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B. 1.617. 2 (Delta) variant predominance&#x2014;nine states, June&#x2013;August 2021. Morb Mortal Wkly Rep. 2021;70(37):1291. doi: 10.15585/mmwr.mm7037e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7037e2</ArticleId><ArticleId IdType="pmc">PMC8445373</ArticleId><ArticleId IdType="pubmed">34529642</ArticleId></ArticleIdList></Reference><Reference><Citation>Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Aghayari Sheikh Neshin S, Khatami A, et al. Effectiveness of COVID-19 vaccines against Delta (B. 1.617. 2) variant: a systematic review and meta-analysis of clinical studies. Vaccines. 2021;10(1):23. doi: 10.3390/vaccines10010023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010023</ArticleId><ArticleId IdType="pmc">PMC8778641</ArticleId><ArticleId IdType="pubmed">35062684</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin S. Covid-19: AstraZeneca vaccine prevents 79% of symptomatic disease and 100% of severe disease, US study finds. British Medical Journal Publishing Group; 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33753451</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, C&#xe1;rdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187&#x2013;201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, C&#xe1;rdenas V, Shukarev G, Grinsztejn B, et al. Final analysis of efficacy and safety of single-dose Ad26. S New Engl J Med. 2022;COV2(9):847&#x2013;60. doi: 10.1056/NEJMoa2117608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2117608</ArticleId><ArticleId IdType="pmc">PMC8849184</ArticleId><ArticleId IdType="pubmed">35139271</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172&#x2013;83. doi: 10.1056/NEJMoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):1&#x2013;15. doi: 10.1186/s12916-022-02397-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02397-y</ArticleId><ArticleId IdType="pmc">PMC9126103</ArticleId><ArticleId IdType="pubmed">35606843</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: background document to the WHO interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac, 24 May 2021. World Health Organization; 2021.</Citation></Reference><Reference><Citation>Ranzani OT, Hitchings MD, Dorion M, D&#x2019;Agostini TL, de Paula RC, de Paula OFP et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377801</ArticleId><ArticleId IdType="pubmed">34417194</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed F, Ganesan S, James A, Zaher WA. Understanding perception and acceptance of Sinopharm vaccine and vaccination against COVID&#x2013;19 in the UAE. BMC Public Health. 2021;21(1):1&#x2013;11. doi: 10.1186/s12889-021-11620-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-11620-z</ArticleId><ArticleId IdType="pmc">PMC8404750</ArticleId><ArticleId IdType="pubmed">34461846</ArticleId></ArticleIdList></Reference><Reference><Citation>Firouzabadi N, Ghasemiyeh P, Moradishooli F, Mohammadi-Samani S. Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. Int Immunopharmacol. 2023:109968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9977625</ArticleId><ArticleId IdType="pubmed">37012880</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, et al. Antiviral and bivalent vaccine efficacy against an omicron XBB. 1.5 isolate. Lancet Infect Dis. 2023;23(4):402&#x2013;3. doi: 10.1016/S1473-3099(23)00070-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00070-1</ArticleId><ArticleId IdType="pmc">PMC9908083</ArticleId><ArticleId IdType="pubmed">36773622</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA. 5&#x2013;and XBB/XBB. 1.5&#x2013;related sublineages among immunocompetent adults&#x2014;increasing Community Access to Testing Program, United States, December 2022&#x2013;January 2023. Morb Mortal Wkly Rep. 2023;72(5):119. doi: 10.15585/mmwr.mm7205e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7205e1</ArticleId><ArticleId IdType="pmc">PMC9927070</ArticleId><ArticleId IdType="pubmed">36730051</ArticleId></ArticleIdList></Reference><Reference><Citation>Monovalent XBB. 1.5 BNT162b2 COVID-19 Vaccine [ https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-09-12/10-covid-modjarrad-508.pdf.</Citation></Reference><Reference><Citation>Looi M-K. What do we know about the Arcturus XBB. 1.16 subvariant? bmj. 2023;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">37192774</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi J. What to know about EG. 5, the latest SARS-CoV-2 variant of interest. JAMA. 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">37594886</ArticleId></ArticleIdList></Reference><Reference><Citation>Feature Article. Medications and COVID-19 Vaccines: What You Should Know [ https://www.chop.edu/news/feature-article-medications-and-covid-19-vaccines-what-you-should-know.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>